Florida Cannabis Laws: Medical Marijuana Rules, Penalties & Legalization

Executive Summary

Florida operates one of the nation's most restrictive medical cannabis programs while maintaining some of the harshest penalties for recreational possession in the Southeast. As of October 2026, Florida allows medical marijuana use for qualified patients through a vertically integrated dispensary system overseen by the Florida Department of Health's Office of Medical Marijuana Use (OMMU). The state authorizes 25 licensed Medical Marijuana Treatment Centers (MMTCs) to cultivate, process, and dispense cannabis products to approximately 850,000 registered patients. Recreational use remains illegal, with possession of more than 20 grams constituting a felony punishable by up to five years imprisonment. Florida voters rejected Amendment 3, a 2024 ballot initiative that would have legalized adult-use cannabis, with the measure receiving 55.9% support—short of the 60% constitutional threshold required for passage. The state's cannabis framework reflects ongoing tension between expanding patient access, maintaining regulatory control through vertical integration, and preserving criminal penalties that disproportionately affect communities of color. Florida's medical program generated $2.1 billion in sales during 2025, making it the third-largest medical market nationally behind California and Illinois.

Why Florida Cannabis Laws Matter

Florida's cannabis policies directly affect 22 million residents, 850,000 medical patients, and a $2.1 billion industry while serving as a bellwether for Southern cannabis reform. The state's approach influences regional policy across the Southeast, where only three states have legalized medical use and none permit recreational consumption. Florida's medical program serves more registered patients than any state except California, with qualifying conditions ranging from cancer and epilepsy to PTSD and chronic pain. The state's vertical integration model—requiring licensees to control cultivation, processing, and retail—concentrates market power among 25 operators including Trulieve (which controls approximately 50% of market share), Curaleaf, and Surterra Wellness. The economic stakes extend beyond direct sales. Florida's cannabis industry employs approximately 15,000 workers in cultivation, retail, and ancillary services, with average dispensary wages of $16.50 per hour according to 2025 OMMU workforce data. The state collected $145 million in application fees, licensing revenue, and sales taxes from medical cannabis in fiscal year 2025. Failure to legalize recreational use costs Florida an estimated $195 million annually in foregone tax revenue, according to a 2024 analysis by the Florida Policy Institute. Criminal justice implications remain profound. Florida law enforcement made 38,420 arrests for cannabis possession in 2025, down from 58,000 in 2019 but still representing substantial enforcement resources. Black Floridians are arrested for cannabis possession at 2.6 times the rate of white residents despite similar usage rates, according to ACLU data. Possession of more than 20 grams triggers felony charges that carry mandatory driver's license suspension, ineligibility for federal student aid, and barriers to employment and housing.

Background and History: Florida's Path to Medical Cannabis

Florida's journey from absolute prohibition to limited medical access spans three decades of legislative battles, failed ballot initiatives, and constitutional amendments.

Early Prohibition and the Compassionate Use Act (1970s-2014)

Florida criminalized cannabis possession in 1978 under Chapter 893 of the Florida Statutes, classifying marijuana as a Schedule I controlled substance with no accepted medical use. Possession of any amount became a first-degree misdemeanor punishable by up to one year in jail and a $1,000 fine, while possession exceeding 20 grams constituted a third-degree felony carrying up to five years imprisonment. This framework remained essentially unchanged for 36 years. The first crack in Florida's prohibition wall appeared in June 2014 when Governor Rick Scott signed the Compassionate Medical Cannabis Act (Senate Bill 1030), creating a narrow exception for low-THC cannabis oil containing 0.8% or less THC and at least 10% CBD. The law authorized five regional dispensing organizations to cultivate and distribute low-THC products exclusively to patients with cancer or debilitating seizure disorders. This limited program, often called "Charlotte's Web" legislation after the high-CBD strain, served fewer than 1,500 patients by late 2015.

Amendment 2 and Constitutional Authorization (2014-2016)

In November 2014, Florida voters considered Amendment 2, a citizen-initiated constitutional amendment to legalize medical marijuana for a broad range of debilitating conditions. The measure received 57.6% support—falling just short of the 60% supermajority required to amend Florida's constitution. United for Care, the advocacy organization led by Orlando attorney John Morgan, immediately began gathering signatures for a revised 2016 ballot initiative. The 2016 version of Amendment 2 expanded qualifying conditions and strengthened patient protections. On November 8, 2016, Florida voters approved the measure with 71.3% support, enshrining medical cannabis access in Article X, Section 29 of the Florida Constitution. The amendment authorized physicians to certify patients for medical marijuana if they suffer from cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, or "other debilitating medical conditions of the same kind or class" as determined by a licensed physician.

Implementation Legislation and Regulatory Framework (2017-2019)

The Florida Legislature passed Senate Bill 8A in June 2017 to implement Amendment 2, establishing the regulatory structure that governs the state's medical program today. The legislation created the Office of Medical Marijuana Use within the Florida Department of Health to oversee patient registration, physician certification, and MMTC licensing. Critically, SB 8A maintained the vertical integration requirement from the 2014 low-THC law, mandating that licensees control all aspects of production from seed to sale. The 2017 implementation law initially capped the number of MMTCs at 10, with additional licenses triggered when the patient registry reached specified thresholds (one new license per 100,000 registered patients). The legislation prohibited smokable cannabis, limiting patients to oils, tinctures, edibles, and vaporizable products. This smoking ban reflected legislative compromise with opponents who argued that Amendment 2 did not explicitly authorize combustible flower. In March 2019, Governor Ron DeSantis signed Senate Bill 182, repealing the smokable cannabis ban after a Leon County circuit court ruled the prohibition unconstitutional in May 2018. The legislation allowed qualified patients to purchase up to 2.5 ounces of smokable flower every 35 days, with physicians required to complete a separate smoking certification course. SB 182 also expanded the MMTC cap to 22 licenses, with additional licenses available through competitive application processes.

Market Expansion and Vertical Integration Challenges (2020-2024)

Florida's medical cannabis market experienced explosive growth between 2020 and 2024, with active patient registrations increasing from 425,000 to 850,000 and annual sales rising from $1.2 billion to $2.1 billion. The OMMU issued three additional MMTC licenses in 2021, bringing the total to 25 operators. Trulieve emerged as the dominant market player, operating 130 of Florida's approximately 650 dispensaries and capturing roughly 50% of total sales by 2023. The vertical integration model faced mounting criticism from smaller operators, patient advocates, and economists who argued the structure created artificial barriers to entry, limited product diversity, and inflated prices. A 2023 study by Florida International University's Jorge M. Pérez Metropolitan Center found that Florida's medical cannabis prices averaged 18% higher than comparable products in competitive markets like Oklahoma and Michigan. Multiple bills to allow wholesale transactions between licensed cultivators and retailers died in committee between 2021 and 2024, with vertical integration supporters arguing the model ensures product safety and supply chain integrity.

The Amendment 3 Campaign and Defeat (2024)

In November 2024, Florida voters rejected Amendment 3, a constitutional amendment that would have legalized recreational cannabis for adults 21 and older. The measure, funded primarily by Trulieve (which contributed $143 million to the Smart & Safe Florida campaign), received 55.9% support—falling approximately 720,000 votes short of the 60% threshold. Amendment 3 would have allowed adults to possess up to three ounces of cannabis and authorized existing MMTCs to sell recreational products without requiring additional licensing. Governor DeSantis led opposition to Amendment 3, arguing the measure lacked provisions for home cultivation, failed to establish potency limits, and would have created a "marijuana cartel" by granting existing licensees exclusive access to the recreational market. The Vote No on 3 campaign raised $28 million, primarily from DeSantis-aligned political committees and the Florida Chamber of Commerce. Post-election analysis by the University of Florida's Bob Graham Center attributed the measure's defeat to insufficient support among voters over 65 (who opposed it 62-38%) and concerns about the vertical integration monopoly.

Key Players in Florida's Cannabis Landscape

Florida Department of Health Office of Medical Marijuana Use

The OMMU administers Florida's medical cannabis program, maintaining the patient registry, licensing MMTCs, and enforcing compliance with Chapter 381.986 of the Florida Statutes. The office processes approximately 25,000 new patient applications monthly and conducts quarterly inspections of all licensed cultivation and processing facilities. As of September 2026, the OMMU oversees 850,000 active patient registrations and 25 licensed MMTCs operating 650 dispensaries statewide. The office publishes weekly updates on patient counts, physician certifications, and dispensed product volumes at knowthefactsmmj.com.

Trulieve Cannabis Corp.

Trulieve dominates Florida's medical market with approximately 50% market share and 130 retail locations concentrated in the I-4 corridor and South Florida. The Quincy-based company reported $1.05 billion in Florida revenue during 2025, representing 62% of its total corporate sales. Trulieve's political influence extends beyond market dominance—the company contributed $143 million to the Amendment 3 campaign, representing 95% of total pro-legalization funding. CEO Kim Rivers has advocated for maintaining vertical integration while expanding access, arguing the model ensures quality control and prevents diversion to illicit markets.

Curaleaf and Surterra Wellness

Curaleaf operates 65 Florida dispensaries and holds approximately 15% market share, focusing on premium flower products and branded edibles. The company's Florida operations generated $315 million in 2025 revenue. Surterra Wellness, rebranded as Parallel in 2021, operates 45 locations with emphasis on wellness-focused formulations and higher-CBD products. Both companies supported Amendment 3 while advocating for regulatory reforms to allow wholesale transactions and reduce barriers to entry for craft cultivators.

United for Care and Patient Advocacy Organizations

United for Care, the organization that led successful Amendment 2 campaigns in 2014 and 2016, remains Florida's most influential patient advocacy group. The organization opposed Amendment 3, arguing the measure failed to include home cultivation rights and would have perpetuated the vertical integration monopoly. Florida NORML and Regulate Florida advocate for comprehensive legalization with provisions for home growing, social equity licensing, and expungement of prior cannabis convictions.

Governor Ron DeSantis and Legislative Leadership

Governor DeSantis emerged as Amendment 3's most prominent opponent, using executive authority to direct state agencies to publish anti-legalization messaging and appearing at Vote No on 3 rallies across the state. Senate President Kathleen Passidomo and House Speaker Paul Renner supported DeSantis's opposition while signaling openness to medical program reforms including expanded qualifying conditions and increased MMTC licenses. The Republican-controlled legislature has consistently rejected recreational legalization bills while gradually expanding medical access.

Legal and Regulatory Framework

Florida's cannabis laws create a constitutional right to medical access while maintaining criminal penalties for recreational use under Chapter 893 of the Florida Statutes.

Constitutional Foundation: Article X, Section 29

Amendment 2, codified as Article X, Section 29 of the Florida Constitution, establishes that qualifying patients have a right to medical marijuana use for treatment of debilitating conditions. The amendment defines "debilitating medical condition" to include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, and "other debilitating medical conditions of the same kind or class as or comparable to those enumerated." This language grants physicians discretion to certify patients for conditions not explicitly listed if they determine cannabis would likely outweigh potential health risks. The constitutional amendment prohibits discrimination against qualified patients in child custody proceedings, organ transplant eligibility, and parental rights unless the patient's cannabis use creates an unreasonable danger. Landlords cannot refuse to lease to qualified patients solely based on their registry status, though they may prohibit smoking on rental premises. Employers retain the right to maintain drug-free workplace policies and may discipline employees who test positive for cannabis, even if they hold valid medical cards.

Statutory Implementation: Florida Statutes § 381.986

Chapter 381.986 of the Florida Statutes implements Amendment 2's constitutional mandate, establishing the regulatory structure for patient registration, physician certification, and MMTC licensing. The statute requires physicians to complete an eight-hour education course approved by the Florida Medical Association or Florida Osteopathic Medical Association before certifying patients. Physicians must conduct an in-person examination, review the patient's medical history, and determine that the benefits of cannabis use likely outweigh risks before entering a certification into the state registry. Qualified patients may possess up to a 70-day supply of medical cannabis as determined by their certifying physician, with statutory limits of 2.5 ounces of smokable flower per 35-day period. Patients under 18 require certification from two physicians, with one being a pediatric specialist, and may not access smokable products. The statute authorizes caregivers to assist patients who are minors or unable to self-administer, with each caregiver limited to assisting four patients.

Criminal Penalties: Florida Statutes § 893.13

Possession of 20 grams or less of cannabis remains a first-degree misdemeanor under Florida Statutes § 893.13(6)(b), punishable by up to one year in jail, one year of probation, and a $1,000 fine. Conviction triggers automatic suspension of driving privileges for one year under Florida Statutes § 322.055. Possession of more than 20 grams constitutes a third-degree felony carrying up to five years imprisonment and a $5,000 fine. Florida's trafficking statutes impose mandatory minimum sentences for large-quantity possession. Possession of 25 pounds to 2,000 pounds triggers a three-year mandatory minimum and $25,000 fine under § 893.135(1)(a). Possession of 2,000 to 10,000 pounds requires a seven-year mandatory minimum and $50,000 fine, while amounts exceeding 10,000 pounds mandate 15 years imprisonment and a $200,000 fine. These trafficking penalties apply regardless of intent to distribute, making them applicable to cultivation operations.

Local Ordinance Authority

Florida Statutes § 381.986(11) preempts local governments from enacting ordinances that conflict with state medical cannabis law, but municipalities retain authority to regulate dispensary locations through zoning. Cities including Miami Beach, Tampa, and Jacksonville have established buffer requirements prohibiting dispensaries within 500 to 1,000 feet of schools, parks, and substance abuse treatment facilities. Some counties including Polk and Sumter initially banned dispensaries entirely, though most have since adopted zoning frameworks after legal challenges.

State-by-State Context: Florida in Regional Comparison

Florida's medical-only framework places it among the more restrictive cannabis states in the Southeast, where only three states have legalized medical use and none permit recreational consumption.

Florida

Florida operates a constitutional medical program serving 850,000 patients through 25 vertically integrated MMTCs. Patients may possess up to 2.5 ounces of smokable flower per 35 days plus additional non-smokable products. Recreational possession remains a misdemeanor for amounts under 20 grams and a felony above that threshold. The state collected $145 million in cannabis-related revenue during fiscal year 2025. Florida's program ranks third nationally in medical sales volume behind California and Illinois.

Georgia

Georgia authorized low-THC cannabis oil (maximum 5% THC) for eight qualifying conditions in 2015, but delayed licensing production facilities until 2021. The state issued six cultivation licenses in 2022, with the first dispensaries opening in 2024. Georgia's program serves approximately 28,000 registered patients with access limited to oils, tinctures, and capsules—no smokable flower. Possession of marijuana flower remains a misdemeanor for less than one ounce and a felony for larger amounts.

Alabama

Alabama legalized medical cannabis in May 2021 through the Darren Wesley "Ato" Hall Compassion Act, establishing a program for 15 qualifying conditions including cancer, PTSD, and chronic pain. The Alabama Medical Cannabis Commission issued five cultivation licenses and four processing licenses in 2023, with dispensaries expected to open in late 2026. The program prohibits smokable flower, limiting patients to oils, capsules, topicals, and other non-combustible forms. Recreational possession remains illegal with penalties ranging from misdemeanor to felony based on quantity.

Louisiana

Louisiana operates a limited medical program through nine licensed pharmacies that dispense cannabis products to patients with qualifying conditions certified by physicians. The state prohibits smokable flower but allows oils, tinctures, topicals, and metered-dose inhalers. Louisiana's program serves approximately 15,000 patients as of 2026. Possession of up to 14 grams without a medical card carries a $100 fine for first offense, with escalating penalties for subsequent violations.

Virginia

Virginia legalized simple possession of up to one ounce for adults 21 and older in July 2021, making it the first Southern state to decriminalize recreational use. However, the state has not authorized commercial sales, creating a legal possession framework without legal purchase options. Virginia's medical program, established in 2020, serves approximately 55,000 patients through five vertically integrated pharmaceutical processors. The state allows home cultivation of up to four plants per household for adults 21 and older.

Market and Business Implications

Florida's $2.1 billion medical cannabis market operates under vertical integration requirements that concentrate market power among 25 licensed operators while limiting opportunities for craft cultivators and independent retailers.

Vertical Integration and Market Concentration

Florida's seed-to-sale licensing model requires MMTCs to control cultivation, processing, manufacturing, and retail operations within a single corporate structure. This vertical integration mandate creates substantial capital barriers to entry—successful applicants typically invest $15 million to $30 million in cultivation facilities, processing equipment, and retail buildouts before generating revenue. The structure has produced significant market concentration, with the top five operators (Trulieve, Curaleaf, Surterra, MÜV, and Liberty Health Sciences) controlling approximately 85% of total sales. Vertical integration supporters argue the model ensures product safety through chain-of-custody controls and prevents diversion to illicit markets. Critics contend the structure artificially limits competition, inflates prices, and prevents craft cultivators from entering the market. A 2023 Florida International University study found that Florida's medical cannabis prices averaged $47 per eighth-ounce of flower compared to $32 in Oklahoma, which allows wholesale transactions between licensed cultivators and retailers.

Wholesale Reform Proposals

Multiple legislative proposals between 2021 and 2024 sought to allow wholesale transactions between licensed cultivators and retailers, similar to alcohol distribution models. Senate Bill 1954 (2023) would have authorized MMTCs to sell bulk flower and extracted oils to other licensed operators, potentially reducing prices through specialization and competition. The bill passed the Senate Commerce Committee but died in appropriations after opposition from Trulieve and other dominant operators who argued wholesale markets would compromise product safety and traceability.

MSO Expansion Strategies

Multi-state operators view Florida as a critical market given its large patient population and high sales volumes. Curaleaf expanded from 35 to 65 Florida locations between 2022 and 2025 through acquisitions of smaller licensees and organic growth. Verano Holdings entered the Florida market in 2023 by acquiring MÜV's parent company for $850 million, gaining access to 50 dispensaries and cultivation facilities in Ruskin and Eustis. Green Thumb Industries and Cresco Labs have explored Florida entry through acquisition but face limited availability of licenses and high valuations.

Capital Markets and Investment

Florida MMTCs raised approximately $2.3 billion in debt and equity capital between 2020 and 2025, according to Viridian Capital Advisors. Trulieve completed a $350 million senior secured notes offering in 2023 at 9.75% interest to fund expansion and refinance existing debt. Smaller operators face higher capital costs—Surterra's 2024 credit facility carried 12% interest plus warrants, reflecting lender concerns about market concentration and regulatory uncertainty. Florida's rejection of Amendment 3 in November 2024 triggered significant equity devaluations among cannabis operators with substantial Florida exposure. Trulieve's stock declined 47% in the week following the election as investors reassessed growth projections. Curaleaf and other MSOs with diversified geographic footprints experienced smaller declines of 15-20%. Analysts at Cowen & Company reduced 2026 Florida market projections from $3.2 billion (assuming recreational legalization) to $2.4 billion under continued medical-only framework.

Employment and Workforce Development

Florida's cannabis industry employed approximately 15,000 workers as of September 2026, including 8,500 in retail, 4,200 in cultivation, and 2,300 in processing and manufacturing. Average dispensary wages of $16.50 per hour exceed Florida's $12 minimum wage but trail retail positions in recreational markets like Colorado ($19.50) and Massachusetts ($21.00). The industry faces workforce challenges including federal employment restrictions for immigrants and visa holders, limited access to traditional banking for payroll processing, and lack of standardized training programs.

What Experts Say

Policy analysts, medical professionals, and industry leaders offer divergent perspectives on Florida's cannabis framework, with debate centering on vertical integration, patient access, and pathways to recreational legalization. Karen Goldstein, regional director for NORML's Florida chapters, characterized the state's medical program as "accessible in theory but restrictive in practice" during 2025 testimony before the Senate Regulated Industries Committee. Goldstein noted that Florida's physician certification requirements and $75 annual patient registration fee create barriers for low-income patients, while the prohibition on home cultivation forces patients to purchase from high-priced dispensaries. Dr. Gregory Gerdeman, a neuroscientist at Eckerd College who studies cannabinoid pharmacology, described Florida's qualifying condition framework as "appropriately broad" in a 2024 interview with the Tampa Bay Times. According to Gerdeman, the constitutional language allowing physicians to certify patients for conditions "of the same kind or class" as enumerated diagnoses provides necessary flexibility for individualized treatment while maintaining medical oversight. Ben Pollara, executive director of Florida for Care and campaign manager for the 2016 Amendment 2 initiative, argued that Amendment 3's defeat in 2024 reflected voter concerns about corporate control rather than opposition to legalization itself. In a post-election analysis published by the Florida Phoenix, Pollara stated that future legalization efforts must include home cultivation provisions, social equity licensing, and limits on vertical integration to gain supermajority support. State Senator Jeff Brandes, a Republican who sponsored multiple cannabis reform bills before leaving office in 2022, characterized Florida's vertical integration model as "economically inefficient and anticompetitive" during a 2023 presentation to the Florida Chamber of Commerce. Brandes noted that states allowing wholesale transactions typically see 20-30% lower retail prices while maintaining product safety through testing requirements and track-and-trace systems. Morgan Fox, political director for the National Cannabis Industry Association, described Florida as "the most important medical market in the Southeast" in a 2025 industry conference presentation. According to Fox, Florida's regulatory decisions influence policy debates across the region, with Alabama and Georgia modeling aspects of their medical programs on Florida's framework while attempting to avoid its vertical integration limitations.

What's Next: Future Developments and Decision Points

Florida's cannabis policy trajectory through 2028 will be shaped by potential ballot initiatives, legislative reforms, and federal rescheduling decisions.

2026 Legislative Session

The Florida Legislature convened its 2026 regular session on March 3, with multiple cannabis-related bills filed for consideration. Senate Bill 412, sponsored by Senator Shevrin Jones, would expand qualifying conditions to include anxiety disorders, migraines, and opioid use disorder. House Bill 1089 proposes allowing MMTCs to sell wholesale to other licensed operators, potentially reducing vertical integration barriers. Neither bill has advanced beyond committee as of October 2026, with leadership signaling reluctance to pursue major reforms before the 2028 election cycle.

Potential 2028 Ballot Initiative

Cannabis advocacy organizations are exploring a revised recreational legalization initiative for the November 2028 ballot. Regulate Florida announced in June 2026 that it is drafting constitutional amendment language that would include home cultivation rights (six plants per household), social equity licensing provisions, and limits on market concentration. The organization aims to begin signature gathering in January 2027, requiring 891,589 valid signatures to qualify for the ballot. Early polling by the University of North Florida suggests that a legalization measure including home cultivation and equity provisions could achieve 62-64% support—above the 60% constitutional threshold.

Federal Rescheduling Impact

The Drug Enforcement Administration's proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act would not directly change Florida's criminal penalties, which derive from state law rather than federal classification. However, rescheduling would eliminate Internal Revenue Code Section 280E restrictions that currently prevent cannabis businesses from deducting ordinary business expenses on federal tax returns. Florida MMTCs could see effective tax rates decline from 65-75% to 25-30%, potentially enabling price reductions of 10-15% while maintaining profitability.

Expungement and Criminal Justice Reform

Multiple advocacy organizations are pressing for legislation to automatically expunge cannabis possession convictions for amounts that would be legal under a medical or recreational framework. House Bill 891, filed in February 2026, would require automatic expungement of convictions for possession of 20 grams or less and create a petition process for larger amounts. The bill has not received committee hearings as of October 2026. Florida currently has approximately 850,000 residents with cannabis-related criminal records, according to estimates by the Florida Rights Restoration Coalition.

Interstate Commerce Considerations

If federal law changes to permit interstate cannabis commerce, Florida's vertical integration model could face competitive pressure from lower-cost producers in states like Oklahoma and Oregon. MMTCs have begun lobbying for protections against out-of-state competition, arguing that Florida-grown products ensure quality control and support local agriculture. Conversely, patient advocates contend that interstate commerce would reduce prices and increase product diversity, benefiting consumers while challenging incumbent operators.

Further Reading and Primary Sources

• Florida Department of Health Office of Medical Marijuana Use: https://knowthefactsmmj.com
• Florida Statutes Chapter 381.986 (Medical Marijuana): http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0300-0399/0381/0381.html
• Florida Statutes Chapter 893.13 (Drug Abuse Prevention and Control): http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html
• Florida Constitution Article X, Section 29 (Medical Marijuana): https://www.flsenate.gov/Laws/Constitution
• Amendment 2 (2016) Full Text: https://dos.myflorida.com/elections/for-voters/constitutional-amendments/
• OMMU Weekly Updates (Patient Counts and Sales Data): https://knowthefactsmmj.com/about/weekly-updates/
• Florida NORML: https://www.flnorml.org
• Regulate Florida: https://www.regulateflorida.com
• Smart & Safe Florida (Amendment 3 Campaign): https://smartandsafeflorida.com
• Florida Senate Bill 8A (2017 Implementation Legislation): https://www.flsenate.gov/Session/Bill/2017A/8A
• Florida Senate Bill 182 (2019 Smokable Cannabis): https://www.flsenate.gov/Session/Bill/2019/182
• ACLU Florida Cannabis Arrest Data: https://www.aclufl.org
• University of Florida Bob Graham Center Cannabis Policy Research: https://bobgrahamcenter.ufl.edu
• Florida Policy Institute Economic Analysis: https://www.fpi.institute
• Viridian Capital Advisors Florida Market Reports: https://www.viridianca.com